The Cardiac Glycoside ZINC253504760 Induces Parthanatos-type Cell Death and G2/M Arrest Via Downregulation of MEK1/2 Phosphorylation in Leukemia Cells

Overview

Journal Cell Biol Toxicol

Publisher Springer

Specialties Cell Biology
Toxicology

Date 2023 Jun 15

PMID 37322258

Authors

Min Zhou

Joelle C Boulos

Sabine M Klauck

Thomas Efferth

Affiliations

Soon will be listed here.

Abstract

Overcoming multidrug resistance (MDR) represents a major obstacle in cancer chemotherapy. Cardiac glycosides (CGs) are efficient in the treatment of heart failure and recently emerged in a new role in the treatment of cancer. ZINC253504760, a synthetic cardenolide that is structurally similar to well-known GCs, digitoxin and digoxin, has not been investigated yet. This study aims to investigate the cytotoxicity of ZINC253504760 on MDR cell lines and its molecular mode of action for cancer treatment. Four drug-resistant cell lines (P-glycoprotein-, ABCB5-, and EGFR-overexpressing cells, and TP53-knockout cells) did not show cross-resistance to ZINC253504760 except BCRP-overexpressing cells. Transcriptomic profiling indicated that cell death and survival as well as cell cycle (G2/M damage) were the top cellular functions affected by ZINC253504760 in CCRF-CEM cells, while CDK1 was linked with the downregulation of MEK and ERK. With flow cytometry, ZINC253504760 induced G2/M phase arrest. Interestingly, ZINC253504760 induced a novel state-of-the-art mode of cell death (parthanatos) through PARP and PAR overexpression as shown by western blotting, apoptosis-inducing factor (AIF) translocation by immunofluorescence, DNA damage by comet assay, and mitochondrial membrane potential collapse by flow cytometry. These results were ROS-independent. Furthermore, ZINC253504760 is an ATP-competitive MEK inhibitor evidenced by its interaction with the MEK phosphorylation site as shown by molecular docking in silico and binding to recombinant MEK by microscale thermophoresis in vitro. To the best of our knowledge, this is the first time to describe a cardenolide that induces parthanatos in leukemia cells, which may help to improve efforts to overcome drug resistance in cancer. A cardiac glycoside compound ZINC253504760 displayed cytotoxicity against different multidrug-resistant cell lines. ZINC253504760 exhibited cytotoxicity in CCRF-CEM leukemia cells by predominantly inducing a new mode of cell death (parthanatos). ZINC253504760 downregulated MEK1/2 phosphorylation and further affected ERK activation, which induced G2/M phase arrest.

Citing Articles

Advances in non-apoptotic regulated cell death: implications for malignant tumor treatment.

Zhang Y, Yi S, Luan M Front Oncol. 2025; 15:1519119.

PMID: 39949740 PMC: 11821507. DOI: 10.3389/fonc.2025.1519119.

NCAPG-mediated CDK1 promotes malignant progression of non-small cell lung cancer via ERK signaling activation.

Wu Y, Yang M, Chen M, Tian L, Zhu Y, Chen L Am J Cancer Res. 2024; 14(11):5338-5350.

PMID: 39659935 PMC: 11626278. DOI: 10.62347/DNAQ7105.

Anti-Inflammatory and Cancer-Preventive Potential of Chamomile ( L.): A Comprehensive In Silico and In Vitro Study.

Drif A, Yucer R, Damiescu R, Ali N, Abu Hagar T, Avula B Biomedicines. 2024; 12(7).

PMID: 39062057 PMC: 11275008. DOI: 10.3390/biomedicines12071484.

Therapeutic strategies of targeting non-apoptotic regulated cell death (RCD) with small-molecule compounds in cancer.

Jin X, Jin W, Tong L, Zhao J, Zhang L, Lin N Acta Pharm Sin B. 2024; 14(7):2815-2853.

PMID: 39027232 PMC: 11252466. DOI: 10.1016/j.apsb.2024.04.020.

Challenges of Regulated Cell Death: Implications for Therapy Resistance in Cancer.

DAmico M, De Amicis F Cells. 2024; 13(13.

PMID: 38994937 PMC: 11240625. DOI: 10.3390/cells13131083.

References

Abdelfatah S, Fleischer E, Klinger A, Wong V, Efferth T . Identification of inhibitors of the polo-box domain of polo-like kinase 1 from natural and semisynthetic compounds. Invest New Drugs. 2019; 38(1):1-9. DOI: 10.1007/s10637-019-00752-0. View

Andrabi S, Dawson T, Dawson V . Mitochondrial and nuclear cross talk in cell death: parthanatos. Ann N Y Acad Sci. 2008; 1147:233-41. PMC: 4454457. DOI: 10.1196/annals.1427.014. View

Andrabi S, Kim N, Yu S, Wang H, Koh D, Sasaki M . Poly(ADP-ribose) (PAR) polymer is a death signal. Proc Natl Acad Sci U S A. 2006; 103(48):18308-13. PMC: 1838747. DOI: 10.1073/pnas.0606526103. View

Ayogu J, Odoh A . Prospects and Therapeutic Applications of Cardiac Glycosides in Cancer Remediation. ACS Comb Sci. 2020; 22(11):543-553. DOI: 10.1021/acscombsci.0c00082. View

Barbosa R, Acevedo L, Marmorstein R . The MEK/ERK Network as a Therapeutic Target in Human Cancer. Mol Cancer Res. 2020; 19(3):361-374. PMC: 7925338. DOI: 10.1158/1541-7786.MCR-20-0687. View

Bessen H . Therapeutic and toxic effects of digitalis: William Withering, 1785. J Emerg Med. 1986; 4(3):243-8. DOI: 10.1016/0736-4679(86)90048-x. View

Bock F, Tait S . Mitochondria as multifaceted regulators of cell death. Nat Rev Mol Cell Biol. 2019; 21(2):85-100. DOI: 10.1038/s41580-019-0173-8. View

Calonge T, OConnell M . Turning off the G2 DNA damage checkpoint. DNA Repair (Amst). 2007; 7(2):136-40. PMC: 2233850. DOI: 10.1016/j.dnarep.2007.07.017. View

Caunt C, Sale M, Smith P, Cook S . MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road. Nat Rev Cancer. 2015; 15(10):577-92. DOI: 10.1038/nrc4000. View

10.

Cowley S, PATERSON H, Kemp P, Marshall C . Activation of MAP kinase kinase is necessary and sufficient for PC12 differentiation and for transformation of NIH 3T3 cells. Cell. 1994; 77(6):841-52. DOI: 10.1016/0092-8674(94)90133-3. View

11.

Daugas E, Nochy D, Ravagnan L, Loeffler M, Susin S, Zamzami N . Apoptosis-inducing factor (AIF): a ubiquitous mitochondrial oxidoreductase involved in apoptosis. FEBS Lett. 2000; 476(3):118-23. DOI: 10.1016/s0014-5793(00)01731-2. View

12.

Daugas E, Susin S, Zamzami N, Ferri K, Irinopoulou T, Larochette N . Mitochondrio-nuclear translocation of AIF in apoptosis and necrosis. FASEB J. 2000; 14(5):729-39. View

13.

Denicolai E, Baeza-Kallee N, Tchoghandjian A, Carre M, Colin C, Jiglaire C . Proscillaridin A is cytotoxic for glioblastoma cell lines and controls tumor xenograft growth in vivo. Oncotarget. 2014; 5(21):10934-48. PMC: 4279420. DOI: 10.18632/oncotarget.2541. View

14.

Doyle L, Yang W, Abruzzo L, Krogmann T, Gao Y, Rishi A . A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci U S A. 1998; 95(26):15665-70. PMC: 28101. DOI: 10.1073/pnas.95.26.15665. View

15.

Dumontet C, Jordan M . Microtubule-binding agents: a dynamic field of cancer therapeutics. Nat Rev Drug Discov. 2010; 9(10):790-803. PMC: 3194401. DOI: 10.1038/nrd3253. View

17.

El-Seedi H, Khalifa S, Taher E, Farag M, Saeed A, Gamal M . Cardenolides: Insights from chemical structure and pharmacological utility. Pharmacol Res. 2018; 141:123-175. DOI: 10.1016/j.phrs.2018.12.015. View

18.

Flaherty K, Infante J, Daud A, Gonzalez R, Kefford R, Sosman J . Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med. 2012; 367(18):1694-703. PMC: 3549295. DOI: 10.1056/NEJMoa1210093. View

19.

Fremin C, Meloche S . From basic research to clinical development of MEK1/2 inhibitors for cancer therapy. J Hematol Oncol. 2010; 3:8. PMC: 2830959. DOI: 10.1186/1756-8722-3-8. View

20.

Gavet O, Pines J . Progressive activation of CyclinB1-Cdk1 coordinates entry to mitosis. Dev Cell. 2010; 18(4):533-43. PMC: 3325599. DOI: 10.1016/j.devcel.2010.02.013. View

21.

Gurel E, Karvar S, Yucesan B, Eker I, Sameeullah M . An Overview of Cardenolides in Digitalis - More Than a Cardiotonic Compound. Curr Pharm Des. 2017; 23(34):5104-5114. DOI: 10.2174/1381612823666170825125426. View